Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers. - Wikidata - awgldk - TriplyDB

Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers.

Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers.

http://www.wikidata.org/entity/Q34615545

about

TRAPP Complexes in Secretion and Autophagy In sickness and in health: the role of TRAPP and associated proteins in disease Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression Elevated NIBP/TRAPPC9 mediates tumorigenesis of cancer cells through NFκB signaling A bead-based western for high-throughput cellular signal transduction analyses.IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma.Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients.A new role of the Rac-GAP β2-chimaerin in cell adhesion reveals opposite functions in breast cancer initiation and tumor progression.Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer.RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis.Adaptive stress signaling in targeted cancer therapy resistance.Identification of novel therapeutic target genes in acquired lapatinib-resistant breast cancer by integrative meta-analysis.Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells.RAC1 GTPase promotes the survival of breast cancer cells in response to hyper-fractionated radiation treatment.

P2860

Q26749341-6B340062-4B39-45B5-A462-D04F3419F960 Q27026407-814A21AF-4332-4DDD-BA9C-C4D8C50C885A Q28544422-02840C54-CAAF-4CDA-BE22-88258A6B6172 Q33822560-8A036186-C412-44B2-8293-6080E5D614EC Q33991817-63A0338A-756B-45A8-83FF-8296B6493A6B Q35742493-D10C991E-C649-493F-BEC9-C885ED499009 Q36141854-35CDE2DF-A8E6-40F7-A02D-E23361F7FFE8 Q36413323-1B0FE60A-201E-4BD4-9A35-975192473595 Q36729467-BA472C72-E9E1-4693-BEB5-F3C5D6ADA28F Q37317542-D2619C66-1EC5-4655-8C49-480E8EDAD1F8 Q37665209-DE499C7E-1BCD-4C47-BAFA-4A8E78EE8DFA Q38145091-CDDB3937-913B-4D9E-9C9B-413441F7C493 Q38363739-4992D79F-8BC3-43F1-9C86-E523FCE0BBBE Q38457923-769FE532-661E-411C-AE18-6F9F0FB7BF8C Q38812867-AC0E9D3E-2E96-4CBF-97FE-EC4CDEF8F3CD Q38824661-2C86276E-BA3F-4917-A422-76976BD33656 Q41850545-E0322ABF-2A46-4DFB-BE6D-8556B6F51CEA Q42079499-5D61332A-81E7-4E7C-AC8C-96DBC20BCB09

P2860

Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers.

http://www.wikidata.org/entity/Q34615545

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Identification of novel determ ...... ib in ERBB2-amplified cancers.

@ast

Identification of novel determ ...... ib in ERBB2-amplified cancers.

@en

Identification of novel determ ...... ib in ERBB2-amplified cancers.

@nl

type

label

Identification of novel determ ...... ib in ERBB2-amplified cancers.

@ast

Identification of novel determ ...... ib in ERBB2-amplified cancers.

@en

Identification of novel determ ...... ib in ERBB2-amplified cancers.

@nl

prefLabel

Identification of novel determ ...... ib in ERBB2-amplified cancers.

@ast

Identification of novel determ ...... ib in ERBB2-amplified cancers.

@en

Identification of novel determ ...... ib in ERBB2-amplified cancers.

@nl

P1433

Q34615545-13F40438-7066-49CD-B010-6E701AEEA537

P1476

Q34615545-D8A38BC3-C0E7-4EEA-B5BC-9B8EF07187B2

P2093

Q34615545-0826380D-4C1F-4E7A-A1C9-76D1AD8FA2D2

Q34615545-0A961BB9-FFAB-4EC5-8EE3-C793FAFBA006

Q34615545-463E1337-E46B-4EF9-B417-4A94CCF58CA3

Q34615545-6B8E29D4-7486-4012-BE60-685A9343D5AA

Q34615545-904CD603-6552-4ED2-ADBC-BECD19DE2611

Q34615545-A34F0C13-FC7B-4342-8282-63B5A8810808

Q34615545-B9302805-1928-4A03-8C52-B5C460E006FA

P2860

Q34615545-05693A9C-CFD3-4F95-A435-12C418CA42F0

Q34615545-07A50BD1-DE32-44B3-9BD1-F0C35794BEB9

Q34615545-0BD2343F-C343-4B86-8A98-3CC0391F0348

Q34615545-110D7B3A-28A2-4379-8AEA-F924C025D1C8

Q34615545-193E8789-329A-4F84-A830-F0C54C90B181

Q34615545-1DBE3BCD-1A64-47B7-920C-012AD1AB1209

Q34615545-31D69EFB-1E8B-4B3F-BB94-954F805499AE

Q34615545-32AA3E54-2AE9-49FC-9014-AC355DAE5995

Q34615545-360102BC-BC22-40EC-B5E3-DDED46A41453

Q34615545-397B3565-3D0A-4C59-B064-195F4C6DD95D

P2888

Q34615545-49171448-59DC-4FCB-A42C-4B2861E7936B

P304

Q34615545-F37C010A-7D25-4CB1-9602-73E6E036FA65

P31

Q34615545-81E87EBE-2E59-4330-B034-7D5B7D17249D

P356

Q34615545-E7476147-74D0-4F64-81E2-F957E271B9A6

P407

Q34615545-1D1BC983-9839-4A85-BDCD-F5F0F42EF805

P433

Q34615545-D1A55B32-331B-4FD0-B839-2733EC77E67D

P478

Q34615545-9EBB4021-89D3-4160-9FA6-D58A46991446

P50

Q34615545-08DDE8CC-DB08-40DF-A2B7-90283A4328AE

Q34615545-AAD49FBA-E5FA-4DFC-A1E5-BC1CA6973C5F

Q34615545-F2B5AF5D-8A0E-4C5C-9604-AE5104B7ABA6

P577

Q34615545-84D1EE94-3D3B-4F00-BC62-696C5635AB0A

P6179

Q34615545-36A79DDE-78DB-46AC-A3FD-919AD2EDFA91

P698

Q34615545-BEDD149E-F4B7-4266-892F-9E473219E2F9

P356

P1433

P1476

Identification of novel determ ...... ib in ERBB2-amplified cancers.

@en

P2093

A Mackay

http://www.w3.org/2001/XMLSchema#string

D Wetterskog

http://www.w3.org/2001/XMLSchema#string

I Chong

http://www.w3.org/2001/XMLSchema#string

J S Reis-Filho

http://www.w3.org/2001/XMLSchema#string

K-K Shiu

http://www.w3.org/2001/XMLSchema#string

M Lambros

http://www.w3.org/2001/XMLSchema#string

T Meijer

http://www.w3.org/2001/XMLSchema#string

P2860

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

TRAPP I implicated in the specificity of tethering in ER-to-Golgi transport.

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

P2888

P304

966-976

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/ONC.2013.41

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Christopher J Lord

David Cunningham

P577

2013-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1052013034

http://www.w3.org/2001/XMLSchema#string

P698

23474757

http://www.w3.org/2001/XMLSchema#string